{"id":"ntq1062-fulvestrant","safety":{"commonSideEffects":[{"rate":null,"effect":"Hot flashes"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Vaginal bleeding"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NTQ1062 functions as a SERD that degrades the estrogen receptor protein, while fulvestrant is a selective estrogen receptor modulator that competitively binds and antagonizes the estrogen receptor. Together, this combination provides dual mechanisms to suppress estrogen receptor-driven proliferation in hormone receptor-positive breast cancer cells, potentially overcoming resistance to standard endocrine therapies.","oneSentence":"NTQ1062 is a selective estrogen receptor degrader (SERD) combined with fulvestrant, an estrogen receptor antagonist, to block estrogen signaling in hormone receptor-positive breast cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:23:37.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hormone receptor-positive, HER2-negative metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT07393321","phase":"PHASE3","title":"A Phase III Clinical Trial of NTQ1062 in Combination With Fulvestrant for the Treatment of Advanced or Metastatic HR+/HER2- Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2026-02-10","conditions":"HR Positive/HER2 Negative Advanced or Metastatic Breast Cancer","enrollment":210},{"nctId":"NCT06172322","phase":"PHASE1","title":"A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer","status":"UNKNOWN","sponsor":"Nanjing Chia-tai Tianqing Pharmaceutical","startDate":"2023-12-28","conditions":"HR Positive/HER-2 Negative Breast Cancer","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NTQ1062+Fulvestrant","genericName":"NTQ1062+Fulvestrant","companyName":"Nanjing Chia-tai Tianqing Pharmaceutical","companyId":"nanjing-chia-tai-tianqing-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NTQ1062 is a selective estrogen receptor degrader (SERD) combined with fulvestrant, an estrogen receptor antagonist, to block estrogen signaling in hormone receptor-positive breast cancer. Used for Hormone receptor-positive, HER2-negative metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}